VISCHER advises Sonetik in a financing to fund further growth in the US. The participants in this Series A2 financing include existing investors, BB Biotech Ventures, and new investors joining the consortium, Aeris Capital. The VISCHER consisted of Matthias Staehelin and Marius Meier (both Corporate).